Neusspray Xylometazoline Hcl Etos (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. When sprayed into the nose it stimulates α1‑ and α2‑receptors on the blood vessels of the nasal mucosa, causing vasoconstriction. This reduces blood flow, diminishes mucosal edema, and quickly clears the nasal passages.

The exact dosing regimen is determined by the prescribing healthcare professional based on the patient’s age, condition, and response. Typically, adults may be instructed to spray one to two actuations per nostril every 10‑12 hours, not exceeding the recommended maximum duration of use.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so it should only be used if the potential benefit justifies the potential risk. Women who are pregnant or breastfeeding should consult their physician before use.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details and any necessary import documentation.

Neusspray Xylometazoline contains Xylometazoline Hydrochloride, an alpha‑adrenergic agonist similar to oxymetazoline but with a slightly longer duration of action. Both provide rapid decongestion, yet Xylometazoline may be preferred in some regions due to regulatory status or formulation differences. Choice depends on clinical response, tolerability and local guidelines.

Store the nasal spray at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed when not in use and retain it in the original packaging to protect the formulation. Do not freeze or refrigerate the product, as temperature extremes can affect spray performance.

The spray is applied directly into each nostril while the head is upright. Gently insert the nozzle into the nostril, press the actuator to release the recommended number of sprays, and then repeat in the other nostril if instructed. Avoid blowing the nose immediately after administration to allow optimal absorption.

Serious adverse events, although rare, include severe hypertension, cardiac arrhythmias, rebound nasal congestion (rhinitis medicamentosa) after prolonged use, nasal ulceration or perforation, and anaphylactic reactions. Patients should discontinue use and seek medical attention if they experience any of these severe symptoms.

Neusspray Xylometazoline should be avoided in children younger than six years unless a physician advises otherwise, in individuals with known hypersensitivity to Xylometazoline or any excipients, and in patients with uncontrolled hypertension, severe cardiovascular disease, or those taking monoamine oxidase inhibitors. Consultation with a healthcare provider is essential before use in these groups.